• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Sequential chemotherapy of malignant non-Hodgkin's lymphoma of high degree of malignancy in stages III and IV].

作者信息

Mitrou P S, Fischer M, Bergmann L, Hübner K

出版信息

Onkologie. 1982 Oct;5(5):222-7. doi: 10.1159/000215007.

DOI:10.1159/000215007
PMID:6760023
Abstract

A sequential combination chemotherapy was used in the treatment of advanced high-grade malignant non-Hodgkins' lymphomas (NHL) from July 1978 to August 1980. The lymphomas were classified according to the Kiel-classification. Cyclophosphamide, vincristine, bleomycin, prednisone (phase A) were followed by a combination of adriamycin, cytosine arabinoside, 6-thioguanine and prednisone (phase B). Patients received four cycles of both combinations. No maintenance therapy was given. 20 patients with centroblastic, lymphoblastic or immunoblastic NHL were included in the study. The overall remission rate was 95% (19 out of 20 patients). 15 (75%) patients entered complete remission. The median duration of complete remission was 28.7 months. The probable survival rate of the patients entering complete remission is 64.5% at two years. Clinical prognostic factors, bone marrow infiltration, extralymphatic organ involvement other than skin and a tumor mass greater than 10 cm in diameter in a single location significantly affected remission induction and survival. All patients with favourable prognosis are still alive in unmaintained complete remission 14 to 38 months after start of treatment. Patients with unfavourable prognosis had a complete response rate of 64% and a median survival of 14.8 months.

摘要

相似文献

1
[Sequential chemotherapy of malignant non-Hodgkin's lymphoma of high degree of malignancy in stages III and IV].
Onkologie. 1982 Oct;5(5):222-7. doi: 10.1159/000215007.
2
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.复发侵袭性淋巴瘤的治疗:含与不含高剂量治疗及干细胞救援的方案
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12.
3
Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.大剂量COMLA(环磷酰胺、阿糖胞苷、长春新碱和甲氨蝶呤,随后使用亚叶酸钙和泼尼松)联合CHOP(环磷酰胺、多柔比星、长春新碱和泼尼松)治疗预后极差的淋巴瘤的疗效
Cancer Treat Rep. 1986 Aug;70(8):953-8.
4
[Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma].环磷酰胺、阿霉素、长春新碱、博来霉素及泼尼松(CHOP-博来霉素)联合化疗用于晚期非霍奇金淋巴瘤
Gan To Kagaku Ryoho. 1983 May;10(5):1266-71.
5
Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group.非霍奇金淋巴瘤基尔分类的临床及预后相关性:基尔淋巴瘤研究组前瞻性多中心研究结果
Hematol Oncol. 1984 Jul-Sep;2(3):269-306. doi: 10.1002/hon.2900020306.
6
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.泼尼松氮芥、米托蒽醌(PmM)与环磷酰胺、长春新碱、泼尼松(COP)治疗晚期低度非霍奇金淋巴瘤。德国低度淋巴瘤研究组
Leukemia. 1996 May;10(5):836-43.
7
[Adriamycin for the treatment of non HOdgkin's lymphomas (author's transl)].阿霉素治疗非霍奇金淋巴瘤(作者译)
Sem Hop. 1981;57(41-42):1685-90.
8
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.人重组干扰素α-2a维持Ⅲ期和Ⅳ期低度恶性非霍奇金淋巴瘤患者的缓解状态。欧洲癌症研究与治疗组织淋巴瘤协作组
J Clin Oncol. 1998 Jan;16(1):41-7. doi: 10.1200/JCO.1998.16.1.41.
9
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.惰性淋巴瘤患者采用联合化疗后使用免疫毒素(抗B4阻断型蓖麻毒素):一项II期研究结果
Cancer J. 2000 May-Jun;6(3):146-50.
10
[Chemotherapy in non-Hodgkin's lymphomas (author's transl)].非霍奇金淋巴瘤的化疗(作者译)
Strahlentherapie. 1977 May;153(5):283-92.